File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Association between Serum Galectin-3 and Advanced Glycation End Products in Type 2 Diabetes

TitleAssociation between Serum Galectin-3 and Advanced Glycation End Products in Type 2 Diabetes
Authors
Issue Date2017
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
The 77th American Diabetes Association (ADA) Scientific Sessions, San Diego, California, USA, 9-13 June 2017. In Diabetes, 2017, v. 66 n. Suppl. 1, p. A-138, abstract no. 526-P How to Cite?
AbstractGalectin-3, a member of the multifunctional galectin family, acts a broad-spectrum biological response modifier and is involved in tissue fibrosis, immunity, and inflammatory response. The role of galectin-3 in diabetic complications is unclear and animal studies have provided evidence for protective and detrimental functions of galectin-3. Although galectin-3 is a mediator of inflammation and fibrosis, it is also a scavenger receptor for advanced glycation end products (AGEs) and stimulates their degradation. We have investigated whether serum galectin-3 level is related to circulating AGEs and/or inflammation in type 2 diabetic patients with and without chronic kidney disease (CKD). 270 type 2 diabetic patients (30% with CKD and eGFR <60 ml/min/1.73m2) and 230 controls were recruited. Serum galectin-3 and AGEs were assayed by ELISA and plasma high sensitivity C-reactive protein (CRP) was measured by immunoturbidimetric assay. Diabetic patients had higher HbA1c, AGEs (4.46 ± 1.06 unit/ml (CKD+); 4.10 ± 0.98 (CKD-); 3.56 ± 0.99 (control); ANOVA p<0.01) and CRP levels than controls. Serum galectin-3 was highest in those with CKD (9.07 ± 2.64 ng/ml (CKD+); 7.48 ± 2.36 (CKD-); 5.36 ± 1.65 (control); ANOVA p<0.01). Serum glaectin-3 correlated with AGEs (r=0.34, p<0.01), eGFR (r=-0.35, p<0.01) and age (r=0.25, p<0.01) but there were no associations with duration of diabetes, HbA1c or CRP. The association with AGEs remained significant even after excluding subjects with CKD (r=0.30, p<0.01). On linear regression analysis, serum AGEs and eGFR were independent determinants of serum galectin-3 after adjusting for age, gender, body mass index, and smoking, accounting for 10% and 12% of the variability respectively (p<0.01). In conclusion, serum galectin-3 was increased in type 2 diabetic patients with and without CKD, and serum level was associated with AGEs and renal function but not with inflammation. The role of galectin-3 in diabetic complications in humans remains to be determined.
DescriptionPoster Presentation
Persistent Identifierhttp://hdl.handle.net/10722/248649
ISSN
2019 Impact Factor: 7.72
2015 SCImago Journal Rankings: 5.185

 

DC FieldValueLanguage
dc.contributor.authorTan, KCB-
dc.contributor.authorShiu, SWM-
dc.contributor.authorWong, Y-
dc.date.accessioned2017-10-18T08:46:27Z-
dc.date.available2017-10-18T08:46:27Z-
dc.date.issued2017-
dc.identifier.citationThe 77th American Diabetes Association (ADA) Scientific Sessions, San Diego, California, USA, 9-13 June 2017. In Diabetes, 2017, v. 66 n. Suppl. 1, p. A-138, abstract no. 526-P-
dc.identifier.issn0012-1797-
dc.identifier.urihttp://hdl.handle.net/10722/248649-
dc.descriptionPoster Presentation-
dc.description.abstractGalectin-3, a member of the multifunctional galectin family, acts a broad-spectrum biological response modifier and is involved in tissue fibrosis, immunity, and inflammatory response. The role of galectin-3 in diabetic complications is unclear and animal studies have provided evidence for protective and detrimental functions of galectin-3. Although galectin-3 is a mediator of inflammation and fibrosis, it is also a scavenger receptor for advanced glycation end products (AGEs) and stimulates their degradation. We have investigated whether serum galectin-3 level is related to circulating AGEs and/or inflammation in type 2 diabetic patients with and without chronic kidney disease (CKD). 270 type 2 diabetic patients (30% with CKD and eGFR <60 ml/min/1.73m2) and 230 controls were recruited. Serum galectin-3 and AGEs were assayed by ELISA and plasma high sensitivity C-reactive protein (CRP) was measured by immunoturbidimetric assay. Diabetic patients had higher HbA1c, AGEs (4.46 ± 1.06 unit/ml (CKD+); 4.10 ± 0.98 (CKD-); 3.56 ± 0.99 (control); ANOVA p<0.01) and CRP levels than controls. Serum galectin-3 was highest in those with CKD (9.07 ± 2.64 ng/ml (CKD+); 7.48 ± 2.36 (CKD-); 5.36 ± 1.65 (control); ANOVA p<0.01). Serum glaectin-3 correlated with AGEs (r=0.34, p<0.01), eGFR (r=-0.35, p<0.01) and age (r=0.25, p<0.01) but there were no associations with duration of diabetes, HbA1c or CRP. The association with AGEs remained significant even after excluding subjects with CKD (r=0.30, p<0.01). On linear regression analysis, serum AGEs and eGFR were independent determinants of serum galectin-3 after adjusting for age, gender, body mass index, and smoking, accounting for 10% and 12% of the variability respectively (p<0.01). In conclusion, serum galectin-3 was increased in type 2 diabetic patients with and without CKD, and serum level was associated with AGEs and renal function but not with inflammation. The role of galectin-3 in diabetic complications in humans remains to be determined.-
dc.languageeng-
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/-
dc.relation.ispartofDiabetes-
dc.titleAssociation between Serum Galectin-3 and Advanced Glycation End Products in Type 2 Diabetes-
dc.typeConference_Paper-
dc.identifier.emailTan, KCB: kcbtan@hkucc.hku.hk-
dc.identifier.emailShiu, SWM: swmshiu@hku.hk-
dc.identifier.emailWong, Y: ywong@hku.hk-
dc.identifier.authorityTan, KCB=rp00402-
dc.identifier.hkuros282051-
dc.identifier.volume66-
dc.identifier.issueSuppl. 1-
dc.identifier.spageA-138-
dc.identifier.epageA-138-
dc.publisher.placeUnited States-
dc.identifier.issnl0012-1797-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats